Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $24.80 USD
Change Today -0.49 / -1.94%
Volume 61.0K
FLXN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 11:55 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

flexion therapeutics inc (FLXN) Snapshot

Open
$25.21
Previous Close
$25.29
Day High
$25.63
Day Low
$24.37
52 Week High
03/20/15 - $30.37
52 Week Low
09/3/14 - $12.41
Market Cap
533.2M
Average Volume 10 Days
118.2K
EPS TTM
$-1.93
Shares Outstanding
21.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FLEXION THERAPEUTICS INC (FLXN)

Related News

No related news articles were found.

flexion therapeutics inc (FLXN) Related Businessweek News

No Related Businessweek News Found

flexion therapeutics inc (FLXN) Details

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which is in placebo-controlled Phase III clinical trials to treat the patients with moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which is in Phase IIa clinical trials intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

29 Employees
Last Reported Date: 03/24/15
Founded in 2007

flexion therapeutics inc (FLXN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $675.3K
Co-Founder and Chief Medical Officer
Total Annual Compensation: $472.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $412.5K
Compensation as of Fiscal Year 2014.

flexion therapeutics inc (FLXN) Key Developments

Flexion Therapeutics, Inc. Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Flexion Therapeutics, Inc. announced earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $12.544 million compared to $5.849 million a year ago. Loss from operations before income tax was $12.437 million compared to $5.931 million a year ago. Net loss was $12.437 million or $0.58 per basic and diluted share compared to $5.931 million or $0.38 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $21.559 million compared to $12.284 million a year ago. Loss from operations before income tax was $21.610 million compared to $12.473 million a year ago. Net loss was $21.610 million or $1.01 per basic and diluted share compared to $12.473 million or $1.07 per basic and diluted share a year ago.

Flexion Therapeutics, Inc. Secures $30 Million in Debt Financing

Flexion Therapeutics, Inc. announced that it entered into a syndicated senior secured term loan facility with MidCap Financial and Silicon Valley Bank that allows Flexion to borrow up to $30 million at an annual interest rate of 6.25% with a maturity of February 2020, subject to certain conditions and other applicable fees. Flexion has drawn down $15 million under the non-dilutive facility and has the right to repay all borrowed funds and terminate the facility at any time, subject to pre-payment fees. Flexion intends to use the borrowings to finance the expansion of its manufacturing capacity with its contract manufacturing organizations.

Flexion Therapeutics, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Flexion Therapeutics, Inc. announced that they will report Q2, 2015 results on Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLXN:US $24.80 USD -0.49

FLXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FLXN.
View Industry Companies
 

Industry Analysis

FLXN

Industry Average

Valuation FLXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLEXION THERAPEUTICS INC, please visit www.flexiontherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.